Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 4
2019 3
2020 4
2021 3
2022 4
2023 5
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Results by year

Filters applied: . Clear all
Page 1
A phase 1 trial utilizing a pharmacokinetic endpoint to determine the optimal dose of ramucirumab in children and adolescents with relapsed or refractory solid tumors, including central nervous system tumors.
Pilbeam KL, Pradhan K, Croop J, Minard CG, Liu X, Voss SD, Isikwei E, Berg SL, Reid JM, Fox E, Weigel BJ. Pilbeam KL, et al. Pediatr Blood Cancer. 2024 Mar;71(3):e30817. doi: 10.1002/pbc.30817. Epub 2024 Jan 8. Pediatr Blood Cancer. 2024. PMID: 38189770 Clinical Trial.
EZH2 inhibition: it's all about the context.
Rosen EY, Shukla NN, Glade Bender JL. Rosen EY, et al. J Natl Cancer Inst. 2023 Nov 8;115(11):1246-1248. doi: 10.1093/jnci/djad141. J Natl Cancer Inst. 2023. PMID: 37682251 No abstract available.
Children's Oncology Group's 2023 blueprint for research.
Hawkins DS, Gore L. Hawkins DS, et al. Pediatr Blood Cancer. 2023 Sep;70 Suppl 6(Suppl 6):e30569. doi: 10.1002/pbc.30569. Epub 2023 Jul 11. Pediatr Blood Cancer. 2023. PMID: 37433635 No abstract available.
Wee1 kinase inhibitor adavosertib with radiation in newly diagnosed diffuse intrinsic pontine glioma: A Children's Oncology Group phase I consortium study.
Mueller S, Cooney T, Yang X, Pal S, Ermoian R, Gajjar A, Liu X, Prem K, Minard CG, Reid JM, Nelson M, Haas-Kogan D, Fox E, Weigel BJ. Mueller S, et al. Neurooncol Adv. 2022 May 20;4(1):vdac073. doi: 10.1093/noajnl/vdac073. eCollection 2022 Jan-Dec. Neurooncol Adv. 2022. PMID: 35733515 Free PMC article.
Durable remission for four pediatric patients with high-risk relapsed classical Hodgkin lymphoma treated with brentuximab vedotin plus gemcitabine but without autologous stem cell transplantation: A report from the Children's Oncology Group.
Buhtoiarov IN, Mba NI, Santos CDL, McCarten KM, Metzger ML, Pei Q, Bush R, Baker K, Kelly KM, Cole PD. Buhtoiarov IN, et al. Pediatr Blood Cancer. 2022 Jun;69(6):e29649. doi: 10.1002/pbc.29649. Epub 2022 Mar 26. Pediatr Blood Cancer. 2022. PMID: 35338689 Free PMC article.
23 results